Lataa...
Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting
Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the effica...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Medknow Publications & Media Pvt Ltd
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3830340/ https://ncbi.nlm.nih.gov/pubmed/24251194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.119629 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|